J Bone Miner Res. 2015 Jan;30(1):39-45. doi: 10.1002/jbmr.2315.

Together, these findings suggest that the use of denosumab and teriparatide in combination improves HR-pQCT measures of bone quality more than either drug alone and may be of significant clinical benefit in the treatment of postmenopausal osteoporosis.

Autor: Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • siete + diecinueve =